Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
0.890
-0.030 (-3.26%)
Nov 21, 2024, 1:13 PM EST - Market open

Estrella Immunopharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Jun '24 Jun '23 Jun '22 Jun '21
Selling, General & Admin
2.363.20.660.30.28
Research & Development
6.454.1110.451.390.46
Operating Expenses
8.827.3111.111.690.73
Operating Income
-8.82-7.31-11.11-1.69-0.73
Pretax Income
-8.82-7.31-11.11-1.69-0.73
Income Tax Expense
00---
Net Income
-8.82-7.31-11.11-1.69-0.73
Preferred Dividends & Other Adjustments
----0.61-
Net Income to Common
-8.82-7.31-11.11-1.07-0.73
Shares Outstanding (Basic)
36270--
Shares Outstanding (Diluted)
36270--
Shares Change (YoY)
6450.97%8764.81%---
EPS (Basic)
-0.25-0.27-36.35--
EPS (Diluted)
-0.25-0.27-36.35--
Free Cash Flow
-18.01-16.07-1.34-1.44-0.67
Free Cash Flow Per Share
-0.50-0.59-4.37--
EBIT
-8.82-7.31-11.11-1.69-0.73
Source: S&P Capital IQ. Standard template. Financial Sources.